Difference between revisions of "Treating COVID-19 with Chloroquine"
(Created page with "Category:Article Category:Covid19 {| class="infobox" width=200px |class="publication"|'''Publication''' |- |Title || <ul>[https://academic.oup.com/jmcb/article/12/4/32...") |
|||
| Line 27: | Line 27: | ||
== Major Issues == | == Major Issues == | ||
| − | No major issues identified. | + | No major issues identified at this time. |
== Minor Issues == | == Minor Issues == | ||
| − | No minor issues identified. | + | No minor issues identified at this time. |
== Impact == | == Impact == | ||
Latest revision as of 17:08, 22 July 2020
| Publication | |
| Title | |
| Authors |
|
| Journal | Journal of Molecular Cell Biology |
| Date | April 1, 2020 |
Randomized controlled trial of 22 COVID-19 positive, symptomatic patients treated with either chloroquine 500mg twice daily or Lopinavir/Rotinavir 400/100mg twice daily for 10 days.
All chloroquine treated patients were PCR negative for SARS-CoV-2 by day 13 and 92% of Lopinavir/Rotinavir treated patients were PCR negative by day 14. All chloroquine treated patients were discharged from the hospital by day 14 compared to only 50% of Lopinavir/Rotinavir treated patients.
Of note, the average time from symptom onset to treatment was 2.5 days and 6.5 days in the chloroquine and Lopinavir/Rotinavir groups, respectively (P = < 0.001). This study suggests potential efficacy of chloroquine in treatment of early stage COVID-19 disease.
Major Issues
No major issues identified at this time.
Minor Issues
No minor issues identified at this time.
Impact
This study both supported earlier findings that lopinavir/rotinavir is likely ineffective in treatment of COVID-19 and that early treatment with chloroquine may have efficacy.
Article Revisions
None at this time.